TY - JOUR
T1 - SARS-CoV-2 infection in patients with primary Sjögren syndrome
T2 - Characterization and outcomes of 51 patients
AU - Brito-Zerón, P.
AU - Melchor, Sheila
AU - Seror, R.
AU - Priori, R.
AU - Solans, R.
AU - Kostov, Belchin
AU - Baldini, C.
AU - Carubbi, Francesco
AU - Callejas, Jose Luis
AU - Guisado-Vasco, Pablo
AU - Hernández-Molina, Gabriela
AU - Pasoto, Sandra G.
AU - Valim, V.
AU - Sisó-Almirall, Antoni
AU - Mariette, X.
AU - Carreira, Patricia
AU - Ramos-Casals, M.
AU - Brito-Zerón, P.
AU - Morcillo, C.
AU - Brito-Zerón, P.
AU - Flores-Chávez, A.
AU - Ramos-Casals, M.
AU - Acar-Denizli, N.
AU - Horvath, I. F.
AU - Szanto, A.
AU - Tarr, T.
AU - Seror, R.
AU - Mariette, X.
AU - Mandl, T.
AU - Olsson, P.
AU - Li, X.
AU - Xu, B.
AU - Baldini, C.
AU - Bombardieri, S.
AU - Gottenberg, J. E.
AU - Gandolfo, S.
AU - De Vita, S.
AU - Priori, R.
AU - Giardina, F.
AU - Hernandez-Molina, G.
AU - Sánchez-Guerrero, J.
AU - Kruize, A. A.
AU - Hinrichs, A.
AU - Valim, V.
AU - Isenberg, D.
AU - Solans, R.
AU - Rischmueller, M.
AU - Downie-Doyle, S.
AU - Kwok, S. K.
AU - Knopf, A.
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected].
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.
AB - Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.
KW - comorbidities
KW - COVID-19
KW - outcomes
KW - Primary SS
KW - SARS-Cov-2
UR - http://www.scopus.com/inward/record.url?scp=85108742062&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keaa748
DO - 10.1093/rheumatology/keaa748
M3 - Article
C2 - 33316070
AN - SCOPUS:85108742062
SN - 1462-0324
VL - 60
SP - 2946
EP - 2957
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 6
ER -